Document:

<PAGE>

                                                                  EXHIBIT 10.11

                               SECOND AMENDMENT TO
                        EXCLUSIVE DISTRIBUTION AGREEMENT

     THIS SECOND AMENDMENT TO EXCLUSIVE DISTRIBUTION AGREEMENT (the "Amendment")
is effective as of this June 3, 1999 by and between ZIMMER, INC., a Delaware
corporation ("Distributor"), and ANIKA THERAPEUTICS, INC., a Massachusetts
corporation ("Company"). Reference is hereby made to that certain Exclusive
Distribution Agreement effective as of November 7, 1997, as amended by First
Amendment to Exclusive Distribution Agreement effective as of June 1, 1998,
together with all Annexes and Exhibits thereto (as so amended, the "Agreement"),
by and between Distributor and Company. All capitalized terms used herein and
not defined shall have the meanings given to them in the Agreement.

     WHEREAS, Distributor and Company have previously entered into the Agreement
providing for the exclusive right of Distributor to distribute and sell the
Product in accordance with the terms set forth therein, and the Parties desire
to amend the terms of the Agreement as provided herein.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements of
the Parties contained herein and in the Agreement, the Parties hereby agree as
follows:

SECTION 1. AMENDMENTS. The Agreement is hereby amended as follows:

     1.1 Section 2 of the Agreement shall be amended as follows: (i) the heading
of Section 2(c) shall be changed to "(c) CERTAIN REGULATORY APPROVALS"; and (ii)
there shall be added the following additional paragraph at the end of such
Section:

     "(c) (iv) DISTRIBUTOR RESPONSIBLE COUNTRIES. Notwithstanding anything
contained in this Agreement to the contrary, Distributor shall use commercially
reasonable efforts to obtain all regulatory approvals required to market, sell
and distribute the Product in the countries set forth on Annex C-1 attached
hereto marked with a + (the "Distributor Responsible Countries").

     1.2 Sections 2(d.2), 2(d.3) and 2(d.4) shall be deleted in their entirety
and replaced with the following:

          (d.2) Upon receipt of a Reimbursement Approval(s) for use of the
          Product in the Field of Use by the appropriate governmental body
          and/or private insurers representing in aggregate more than fifty
          percent (50%) of the population in Germany, Distributor shall pay
          Company the one-time nonrefundable sum of $500,000.

          (d.3) Upon receipt of the first Reimbursement Approval(s) for use of
          the Product in the Field of Use by the appropriate governmental body
          and/or private insurers representing in aggregate more than fifty
          percent

<PAGE>

          (50%) of the population in either of the United Kingdom or France,
          Distributor shall pay Company the one-time nonrefundable sum of
          $250,000, and thereafter upon receipt of such Reimbursement
          Approval(s) in such other country, Distributor shall pay Company the
          one-time nonrefundable sum of $125,000.

          (d.4) Upon receipt of the first Reimbursement Approval(s) for use of
          the Product in the Field of Use by the appropriate governmental body
          and/or private insurers representing in aggregate more than fifty
          percent (50%) of the population in any one of the following countries
          (Italy, Sweden or the Netherlands), Distributor shall pay Company the
          one-time nonrefundable sum of $125,000.

     1.3 Section 3 of the Agreement shall be amended to include the following
additional paragraph at the end of such Section:

          "(c) The Company grants to Distributor a right of first offer to
     acquire the rights to market, distribute and sell the Product in Israel,
     Turkey, Spain, Portugal and Egypt (the "Additional Territory") on the
     following terms: If the Company seeks to change its current distributor in
     any of the countries in the Additional Territory, the Company will notify
     Distributor in writing (the date of such notification the "Notification
     Date") before commencing any negotiations with any third party regarding
     such rights. Distributor will have sixty (60) days from the Notification
     Date to indicate its interest in acquiring the right to market, distribute
     and sell the Product in any of such countries. If Distributor does not wish
     to pursue negotiations for the right to market, distribute and sell the
     Product in any such country, or if such sixty (60) day period expires
     without Distributor notifying Company as to its interest, then Company
     shall be free to enter into an agreement with another Person with respect
     to such rights. If prior to the expiration of the sixty (60) day period,
     Distributor expresses in writing its interest in obtaining the right to
     market, distribute and sell the Product in any such country, the parties
     shall enter in to good faith negotiations regarding such rights within the
     ninety (90) day period immediately following the Notification Date. In any
     proposal to acquire the rights to market, distribute and sell the Product
     in any Additional Territory, Distributor shall produce a supplement to the
     Marketing Plan with respect to such country which shall include a
     reasonable incremental increase to the Territory-wide Purchase Requirement
     (up to a maximum of five percent (5%) of Distributor's marketing forecast
     for actual Product sales for such countries). If at the end of such ninety
     (90) day period the parties are unable to reach an agreement and Company
     does not wish to continue the negotiations, as Company shall determine in
     its sole discretion, Company shall be free to enter into an agreement with
     any other Person with respect to such rights. Notwithstanding anything
     contained in this Agreement to the contrary, the Company shall have no
     obligation to seek to change its current distributor in any of the
     countries in the Additional Territory."

                                       2
<PAGE>

     1.4 The table comprising part of Section 4(a) of the Agreement shall be
amended by deleting such table in its entirety and replacing it with the
following:

<TABLE>

<CAPTION>

              CALENDAR                TERRITORY-WIDE                     INCREMENTAL
               YEAR                   UNITS REQUIREMENT*                 MINIMUM*
           --------                   ------------------                 --------
         <S>                         <C>                                <C>
           1998 (Year 1)                   30,000 Units                  30,000 Units
           1999 (Year 2)                   90,000 Units                  30,000 Units
           2000 (Year 3)                  150,000 Units                  30,000 Units
           2001 (Year 4)                  290,000 Units                  40,000 Units
           2002 (Year 5)                  520,000 Units                  45,000 Units
           2003 (Year 6)                  550,000 Units                  50,000 Units
           2004 (Year 7)                  570,000 Units                  70,000 Units
           2005 (Year 8) and              580,000 Units                  80,000 Units
           thereafter annually

</TABLE>

     *    Exclusive of Samples and Demonstration Units

     1.5 Section 4(b) of the Agreement shall be deleted in its entirety and
replaced with the following:

     "(b) Notwithstanding the provisions of Section 4(a), Distributor shall not
be obligated to purchase more than the number of Units per year listed in the
table in Section 4(a) under the column titled "Incremental Minimum" for each
such year until the year in which the U.S. FDA approves the Product for
marketing and sale for use in the treatment of osteoarthritis by injection in
the human knee joint in the Field of Use in the United States. Upon receipt of
such FDA approval, Distributor shall be obligated to purchase in that calendar
year the prorated Year 2 annual Territory-wide Units Requirement which shall be
determined by multiplying the Year 2 annual Territory-wide Units Requirement
(90,000 Units) by a fraction, the numerator of which is the number of days
remaining in the calendar year after the date on which FDA approval is received
and the denominator of which is 365. The Year 3, Year 4, Year 5, Year 6 and Year
7 annual Territory-wide Units Requirement shall apply to the first, second,
third, fourth and fifth calendar years, respectively, immediately succeeding the
calendar year during which the FDA approval is received, and the Year 8 annual
Territory- wide Units Requirement shall apply to each calendar year thereafter
during the Term. For example: if FDA approval is received 6 months into Year 3
then for Year 3, the annual Territory-wide Units Requirement pursuant to the
calculation specified above shall be 45,000 Units (90,000 multiplied by .50);
and for Year 4, the annual Territory-wide Units Requirement shall be 150,000
Units (the Year 3 Territory-wide Units Requirement as applicable to the first
year succeeding the calendar year during which the FDA approval is received).

     All purchases of Product shall have a documented delivery date assigned to
them. For purposes of determining whether or not Distributor has met the annual
Territory-wide Units Requirement for any given year, the documented delivery
date shall be determinative, not the date of actual delivery, if different."

                                       3
<PAGE>

     1.6 Annex C-1 of the Agreement shall be deleted in its entirety and
replaced by Annex C-1 attached hereto.

     1.7 Table 3, (referred to therein as the "Proposed Majority Activities
Budget Summary"), comprising part of the Marketing Plan attached as Annex B to
the Agreement, and Appendix A also comprising part of the Marketing Plan shall
both be amended in the form of Exhibit 1 attached hereto.

     1.8 Section 7(b) of the Agreement shall be amended so that the last two
sentences of such section shall be deleted in their entirety and replaced by the
following:

     "If for any calendar year during the first three (3) years following the
earlier of (i) the First Commercial Sale of the Product by Distribution in any
country in the Territory or (ii) January 1, 1998, the actual Average Selling
Price per Unit for such calendar year exceeds the Estimated Average Selling
Price used for such calendar year, Distributor shall pay to Company within
thirty (30) days of the date the calculation of the actual Average Selling Price
per Unit is deemed final by the Parties as provided in Section 7(c) of the
Agreement, an amount equal to (X) the number of Net Units Sold during such
calendar year multiplied by (Y) thirty-five percent (35%) of the difference
between the actual Average Selling Price per Unit and the Estimated Average
Selling Price used for such calendar year. Thereafter, if for any calendar year
the actual Average Selling Price per Unit for such calendar year exceeds the
Estimated Average Selling Price used for such calendar year, Distributor shall
pay to Company within thirty (30) days of the date the calculation of the actual
Average Selling Price per Unit is deemed final by the Parties as provided in
Section 7(c) of the Agreement, an amount equal to (X) the number of Net Units
Sold during such calendar year multiplied by (Y) forty percent (40%) of the
difference between the actual Average Selling Price per Unit and the Estimated
Average Selling Price used for such calendar year. If for any calendar year
during the first three (3) years following the earlier of (i) the First
Commercial Sale of the Product by Distributor in any country in the Territory or
(ii) January 1, 1998, the Estimated Average Selling Price exceeds the actual
Average Selling Price per Unit, Company shall pay to Distributor within thirty
(30) days of the date the calculation of the actual Average Selling Price per
Unit is deemed final by the Parties as provided in Section 7(c) of this
Agreement an amount equal to (X) the number of Net Units Sold during such
calendar year multiplied by (Y) thirty-five percent (35%) of the difference
between the Estimated Average Selling Price and the actual Average Selling Price
per Unit. Thereafter, if for any calendar year the Estimated Average Selling
Price exceeds the actual Average Selling Price per Unit, Company shall pay to
Distributor within thirty (30) days of the date the calculation of the actual
Average Selling Price per Unit is deemed final by the Parties as provided in
Section 7(c) of this Agreement an amount equal to (X) the number of Net Units
Sold during such calendar year multiplied by (Y) forty percent (40%) of the
difference between the Estimated Average Selling Price and the actual Average
Selling Price per Unit."

     1.9 The first paragraph of Section 17(b) of the Agreement shall be deleted
in its entirety and replaced by the following:

                                       4
<PAGE>

     "(b) Upon the tenth anniversary of the Effective Date, Distributor may, at
Distributor's sole option, choose to extend this Agreement for an additional
period of ten (10) years, which such ten (10) years shall be added to the Term
for each country in the following regions:

     1.   "Americas" Region = Canada, U.S., and Puerto Rico

     2.   "Latin America" Region = Argentina, Bolivia, Brazil, Chile, Columbia,
          Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala,
          Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay,
          Peru, Suriname, Trinidad and Tobago, Uruguay, Venezuela

     3.   "Asia" Region = Australia, China, Hong Kong, Indonesia, South Korea,
          Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand

     4.   "Europe" Region = Austria, Belgium, Denmark, Finland, France, Germany,
          Greece, Italy, Luxembourg, The Netherlands, Norway, Sweden,
          Switzerland, United Kingdom

     5.   "Eastern Europe" Region = Baltic Region (Estonia, Latvia and
          Lithuania), Balkan Region (Romania, Bulgaria, Albania, Croatia,
          Slovenia, Bosnia, Macedonia and Serbia), Czech Republic, Hungary,
          Poland, Russia and other Commonwealth of Independent States
          (specifically excluding Azerbaijan, Turkmenistan, Kazakhstan,
          Kirghizistan, Tachcikistan)

     6.   "Middle East/Africa" Region = Syria, Lebanon, Jordan, Saudi Arabia,
          UAE/Gulf, Africa, South Africa"

SECTION 2. MISCELLANEOUS.

     2.1 Except as specifically amended by this Amendment, the Agreement shall
remain in full force and effect in accordance with its terms and all references
in the Agreement and in this Amendment to the Agreement shall mean the Agreement
as amended hereby.

     2.2 This Amendment may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     2.3 This Amendment shall be governed by and construed in all respects in
accordance with the laws of the State of New York, without giving effect to its
choice of law principles.

                                       5
<PAGE>

         IN WITNESS WHEREOF, the Parties have caused this Amendment to be
executed by their duly authorized representatives.

                                   ANIKA THERAPEUTICS, INC.

                                   By: /S/ J. MELVILLE ENGLE
                                      ----------------------------
                                   Name: J. Melville Engle
                                   Title:   Chairman, President, CEO

                                   ZIMMER, INC.

                                   By: /S/ J. RAYMOND ELLIOTT
                                      ---------------------------
                                   Name: J. Raymond Elliott
                                   Title:   President

                                       6
<PAGE>

                                                     ANNEX C-1
<TABLE>

<CAPTION>

COUNTRIES INCLUDED IN TERRITORY

<S>                                                          <C>
ASIA                                                          AMERICAS
----                                                          --------
Australia                                                     Canada
China*                                                        United States of America
Hong Kong                                                     Puerto Rico
Indonesia
Korea, South                                                  LATIN AMERICA
Malaysia                                                      -------------
New Zealand                                                   Argentina
Philippines                                                   Bolivia
Singapore                                                     Brazil
Taiwan                                                        Chile
Thailand                                                      Columbia
                                                              Costa Rica
EUROPE                                                        Dominican Republic
------                                                        Ecuador
Austria                                                       El Salvador
Belgium                                                       Guatemala
Denmark                                                       Guyana
Finland                                                       Haiti
France                                                        Honduras
Germany                                                       Jamaica
Greece                                                        Mexico
Italy                                                         Nicaragua
Luxembourg                                                    Panama
Netherlands, The                                              Paraguay
Norway                                                        Peru
Sweden                                                        Suriname
Switzerland                                                   Trinidad and Tobago
United Kingdom                                                Uruguay
                                                              Venezuela

</TABLE>

                                       7
<PAGE>

EASTERN EUROPE+
---------------
Baltic Region (Estonia, Latvia and Lithuania)
Balkan Region (Romania, Bulgaria, Albania,
Croatia, Slovenia, Bosnia, Macedonia and
Serbia)
Czech Republic
Hungary
Poland
Russia and other Commonwealth of
Independent States countries (specifically
excluding Azerbaijan, Turkmenistan,
Kazakhstan, Kirghizistan and
Tachcikistan)

MIDDLE EAST/AFRICA+
-------------------
Syria
Lebanon
Jordan
Saudi Arabia
UAE/Gulf
Africa
South Africa

* Subject to the terms and conditions in Section 2(c)(ii)
+ Distributor Responsible Countries

                                       8

<PAGE>

                                    EXHIBIT 1
                                    TABLE #3
                              AMENDED BUDGET SUMMARY

                        ZIMMER, INC./ANIKA THERAPEUTICS, INC.
                            SECOND AMENDMENT PROPOSAL TO
                          EXCLUSIVE DISTRIBUTION AGREEMENT

3)  Proposed Marketing Activities Budget Summary
-----------------------------------------------

    a)  Table 3 comprising part of the Marketing Plan attached as Annex B to
        the Agreement, and Appendix A also comprising part of the Marketing
        Plan shall both be amended in the form of Exhibit 2 as follows:

<TABLE>
<CAPTION>

COUNTRY/                   YEAR 1         YEAR 2          YEAR 3          YEAR 4
REGION                     12 MO.         12 MO.          12 MO.          12 MO.
--------                   ------         ------          ------          ------
<S>                     <C>            <C>             <C>             <C>

Canada/Australia         $1,700,000     $   700,000     $ 1,700,000     TBD
United States                10,000       4,900,000       3,880,000     TBD
Asia                          5,000          10,000       1,000,000     TBD
Europe                    1,170,000       4,540,000       4,300,000     TBD
Latin America               180,000       1,040,000       1,000,000     TBD
CE/ME/SA                    680,000         700,000         760,000     TBD
                         ----------     -----------     -----------
    Total                $3,685,000     $11,890,000     $12,640,000

Contract Contingency        +/- 5%         +/- 15%         +/- 20%           0%
Adj. Annual Commitment   $  184,280     $ 1,785,500     $ 2,528,000     Proposed Budget

                                                  All/Shortfalls/Overspend: M $4,485.7
</TABLE>

TBD: Budget for Year 4 has not been determined. A proposed budget will be
presented to the Steering Committee. All Adjustments will be incorporated
into Year 4 Proposal. Budget is Contingent upon Regulatory Approval in All
Markets and Countries Identified in Annex C1.

<PAGE>

                                    EXHIBIT 1
                                   (CONTINUED)
                               AMENDED APPENDIX A

                        ZIMMER, INC./ANIKA THERAPEUTICS
        SECOND AMENDMENT PROPOSAL TO EXCLUSIVE DISTRIBUTION AGREEMENT

b)  Amended Appendix A: Field Specialist and Support Personnel

<TABLE>
<CAPTION>
                               YEAR ONE         YEAR TWO
PERSONNEL                      12 MONTHS        12 MONTHS
---------                      ---------        ---------
<S>                            <C>              <C>
(Field Sales Specialists)
-------------------------

Canada                               5                5
United States                        0               26
Taiwan                               1                2
Korea                                1                2
Singapore                            1                1
Hong Kong                            1                1
Australia                            1                2
New Zealand                                                 TBD
Latin America                        2                5
Europe                               5               24
CE/ME/SA                             4                4
Total FSS                           21               71

(Support Personnel)
-------------------
Europe:
-------
  Product Mgr.                       1                1
  Sales Specialist                   2                4
  Sales Director                     1                1
Total Europe                         4                6
Latin America:
  Product Mgr.                       1                1
Total Support Personn                5                7

</TABLE>

Specific Additions are predicated upon receipt of Regulatory Approval in each
Country/Region to market ORTHOVISC.

Notes:
------
1.  Budgeted Specialist for the following Markets: Russia, Czech Republic,
    Poland, Hungary
2.  Non-Budgeted: ME/Africa/SA: Local Market distributors to hire Specialists<PAGE>

                                                                   EXHIBIT 10.1

                        [SATCON LETTERHEAD APPEARS HERE]

March 22, 2000

Mr. Sean Moran
3 Creek Drive
Norfolk, MA  01801

Dear Sean:

         Please be advised that if within one year of the occurrence of a Change
in Control Event your employment with SatCon Technology Corporation (the
"Company") is terminated by the Company and there occurs an Involuntary
Termination of your employment, the Company shall continue to pay your salary as
in effect on the date of termination until the date one year after the date of
termination ("Continuation Payments"); PROVIDED, HOWEVER, as a condition to your
receipt of any Continuation Payments you execute and deliver a general release
to the Company in a form reasonably acceptable to the Company within 60 days of
your termination.

         For purposes of this letter, Change in Control Event and Involuntary
Termination shall be defined as follows:

         (a) A "Change in Control Event" shall mean:

              (i) the acquisition by an individual, entity or group (within the
                  meaning of Section 13(d)(3) or 14(d)(2) of the Securities
                  Exchange Act of 1934, as amended (the "Exchange Act")) (a
                  "Person") of beneficial ownership of any capital stock of the
                  Company if, after such acquisition, such Person beneficially
                  owns (within the meaning of Rule 13d-3 promulgated under the
                  Exchange Act) 50% or more of either (x) the then-outstanding
                  shares of common stock of the Company (the "Outstanding
                  Company Common Stock") or (y) the combined voting power of the
                  then-outstanding securities of the Company entitled to vote
                  generally in the election of directors (the "Outstanding
                  Company Voting Securities"); PROVIDED, HOWEVER, that for
                  purposes of this subsection (i), the following acquisitions
                  shall not constitute a Change in Control Event: (A) any
                  acquisition directly from the Company (excluding an
                  acquisition pursuant to the exercise, conversion or exchange
                  of any security exercisable for, convertible into or
                  exchangeable for common stock or voting securities of the
                  Company, unless the Person exercising, converting or
                  exchanging such security acquired such security directly from
                  the Company or an underwriter or agent of the Company), (B)
                  any acquisition by any employee benefit plan (or related
                  trust) sponsored or maintained by the Company or any
                  corporation controlled by the Company, or (C) any acquisition
                  by any corporation pursuant to a Business Combination (as

<PAGE>

                  defined below) which complies with clauses (x) and (y) of
                  subsection (iii) of this definition; or

              (ii)such time as the Continuing Directors (as defined below) do
                  not constitute a majority of the Board (or, if applicable, the
                  Board of Directors of a successor corporation to the Company),
                  where the term "Continuing Director" means at any date a
                  member of the Board (x) who was a member of the Board on the
                  date of this letter or (y) who was nominated or elected
                  subsequent to such date by at least a majority of the
                  directors who were Continuing Directors at the time of such
                  nomination or election or whose election to the Board was
                  recommended or endorsed by at least a majority of the
                  directors who were Continuing Directors at the time of such
                  nomination or election; PROVIDED, HOWEVER, that there shall be
                  excluded from this clause (y) any individual whose initial
                  assumption of office occurred as a result of an actual or
                  threatened election contest with respect to the election or
                  removal of directors or other actual or threatened
                  solicitation of proxies or consents, by or on behalf of a
                  person other than the Board; or

             (iii)the consummation of a merger, consolidation, reorganization,
                  recapitalization or statutory share exchange involving the
                  Company or a sale or other disposition of all or substantially
                  all of the assets of the Company (a "Business Combination"),
                  unless, immediately following such Business Combination, each
                  of the following two conditions is satisfied: (x) all or
                  substantially all of the individuals and entities who were the
                  beneficial owners of the Outstanding Company Common Stock and
                  Outstanding Company Voting Securities immediately prior to
                  such Business Combination beneficially own, directly or
                  indirectly, more than 50% of the then-outstanding shares of
                  common stock and the combined voting power of the
                  then-outstanding securities entitled to vote generally in the
                  election of directors, respectively, of the resulting or
                  acquiring corporation in such Business Combination (which
                  shall include, without limitation, a corporation which as a
                  result of such transaction owns the Company or substantially
                  all of the Company's assets either directly or through one or
                  more subsidiaries) (such resulting or acquiring corporation is
                  referred to herein as the "Acquiring Corporation") in
                  substantially the same proportions as their ownership of the
                  Outstanding Company Common Stock and Outstanding Company
                  Voting Securities, respectively, immediately prior to such
                  Business Combination and (y) no Person (excluding the
                  Acquiring Corporation or any employee benefit plan (or related
                  trust) maintained or sponsored by the Company or by the
                  Acquiring Corporation) beneficially owns, directly or
                  indirectly, 50% or more of the then-outstanding shares of
                  common stock of the Acquiring Corporation, or of the combined
                  voting power of the then-outstanding securities of such
                  corporation entitled to vote generally in the election of

<PAGE>

              directors (except to the extent that such ownership existed
              prior to the Business Combination).

         (b)  "Involuntary Termination" shall include (i) a material adverse
              change in the authority, duties or compensation of Sean Moran
              without your prior consent or (ii) the relocation of your place of
              work more than 100 miles from the Company's executive offices at
              the time of the Change of Control Event.

         If this is in accordance with your understanding, please indicate your
agreement by signing below. This letter shall be void if it is not countersigned
by you and returned to the Company within 10 days of the date of this letter.

                                                     Sincerely,

                                                     /s/ MICHAEL C. TURMELLE
                                                     --------------------------
                                                     Michael Turmelle
                                                     Chief Operating Officer

/s/ SEAN MORAN
--------------------
Sean Moran

3/22/2000
--------------------
Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}]]